Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

NCT02633943 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.

NCT NCT02633943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Lead sponsor
Genetix Biotherapeutics Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
January 31, 2014
Completion date
November 30, 2035
Enrollment
66 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

transfusion-dependent beta-thalassemia